H.C. Wainwright upgraded Rapport Therapeutics' price target from $40 to $66 following positive Phase 2 trial results of RAP-219 for acute bipolar mania. The drug met its primary endpoint, showing significant symptom improvement, and is moving toward late-stage testing. Analysts estimate RAP-219 could reach $1 billion in peak annual sales, boosting investor interest and stock trading volume. The drug is also being studied for focal epilepsy, supporting its potential in large markets.
The news on Rapport Therapeutics' price target increase provides context for readers interested in health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 21, 2026 02:12 WIB: out of 150 priced US health-sector stocks, 133 rose and 16 fell today. Notable movers include Definium Therapeutics Inc. (DFTX) at USD 35.34 with a +7.19% change and a typical hold time of 7 days on Pluang, and Davita Inc (DVA) at USD 173.93 with a -6.99% change and a typical hold time of 115 days, with 76% of Pluang orders buying.
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
MSCI reported better-than-expected results for Q3 2026, with adjusted earnings per share of $5.11 and revenue of $892 million, surpassing estimates. Revenue grew 12.4% year-over-year, driven by recurring subscriptions and asset-based fees, which rose...
Capital One Financial is set to report its Q3 2026 earnings on October 20, with analysts forecasting revenue growth driven by strong credit card activity, including a 23.3% rise in interchange fees and a 2.5% increase in net interest income. However,...
Synchrony Financial reported Q3 2026 earnings per share of $2.68 and revenue of $4.91 billion, both exceeding analyst expectations. However, net profit fell to $892 million from $1.1 billion the previous year due to higher operating costs, even as cr...
